{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994584520832.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/nbt.2725"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/nbt.2725.pdf"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/nbt.2725"}}],"dc:title":[{"@value":"Reassessing target antigens for adoptive T-cell therapy"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994584520833","@type":"Researcher","foaf:name":[{"@value":"Christian S Hinrichs"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994584520832","@type":"Researcher","foaf:name":[{"@value":"Nicholas P Restifo"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"10870156"},{"@type":"EISSN","@value":"15461696"}],"prism:publicationName":[{"@value":"Nature Biotechnology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2013-11","prism:volume":"31","prism:number":"11","prism:startingPage":"999","prism:endingPage":"1008"},"reviewed":"false","dc:rights":["https://www.springernature.com/gp/researchers/text-and-data-mining","https://www.springernature.com/gp/researchers/text-and-data-mining"],"url":[{"@id":"https://www.nature.com/articles/nbt.2725.pdf"},{"@id":"https://www.nature.com/articles/nbt.2725"}],"createdAt":"2013-10-20","modifiedAt":"2025-04-11","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360005518375807104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709589376896","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Generation of tumor antigen-specific murine CD8+ T cells with enhanced anti-tumor activity via highly efficient CRISPR/Cas9 genome editing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643783150080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on “Off-the-Shelf” T Cell Therapy Using iPSC Technology and Gene Editing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866857200384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182096582528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"‘Off-the-shelf’ immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661307516416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661690963712","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694371772950528","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/nbt.2725"},{"@type":"CROSSREF","@value":"10.1038/s41598-019-49834-2_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1093/intimm/dxy006_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1016/j.exphem.2016.10.009_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.3390/cells11020269_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1016/j.ymthe.2024.01.018_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1182/blood-2017-08-802926_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1158/2326-6066.cir-14-0222_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"},{"@type":"CROSSREF","@value":"10.1186/s40880-019-0423-3_references_DOI_OThheTUg0szLne2RkiaHUYJySV2"}]}